A New Approach to Symptom Relief in Atopic Dermatitis: The Role of Upadacitinib
DOI:
https://doi.org/10.56570/jimgs.v4i1.184Keywords:
Upadacitinib, Atopic Dermatitis, JAK Inhibitors, Eczema Treatment, Inflammatory Skin Disease, Clinical Efficacy and SafetyAbstract
Atopic dermatitis (AD) is a common, chronic inflammatory disease that affects millions of individuals worldwide. It is characterized by intense itching, recurrent eczematous lesions, and a relapsing-remitting course, all of which significantly impair quality of life. Conventional treatments, including topical corticosteroids, calcineurin inhibitors, and systemic immunosuppressants, often provide only partial relief or carry risks of adverse effects with prolonged use. The limited efficacy and safety concerns associated with existing therapies have driven interest in targeted approaches that address the underlying immune dysregulation. One such strategy involves inhibition of the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway, which plays a key role in transmitting inflammatory cytokine signals involved in AD pathogenesis. Upadacitinib, a selective JAK1 inhibitor initially approved for immune-mediated conditions such as rheumatoid arthritis and inflammatory bowel disease, has recently gained approval for moderate-to-severe AD, representing a promising addition to the list of current treatment options.References
Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatologic clinics. 2017 Jul 1;35(3):283-9.
Moennig E, Traidl S. Real-world experience with tralokinumab in a patient with recalcitrant atopic dermatitis: A case report. Clinical, Cosmetic and Investigational Dermatology. 2022 Dec 31:2825-30.
Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ, Kunz B. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology. 2020 Dec;34(12):2717-44.
Kim J, Kim BE, Leung DY. Pathophysiology of atopic dermatitis: Clinical implications. InAllergy and asthma proceedings 2019 Mar (Vol. 40, No. 2, p. 84).
Stefanovic N, Flohr C, Irvine AD. The exposome in atopic dermatitis. Allergy. 2020 Jan;75(1):63-74.
LEWIS-JONES S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. International journal of clinical practice. 2006 Aug;60(8):984-92. Volume 10 (03) June 2nd, 2025. Literature Review
Del Giudice A, Giuggioli D, Bertani A, Sandri G. Upadacitinib: One More Option in the Treatment of Patients with Rheumatoid Arthritis and Crohn's Disease. CLINICAL CASE REPORTS INTERNATIONAL. 2024;8:1-3.
Mohamed ME, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: Mechanism of action, clinical, and translational science. Clinical and translational science. 2024 Jan;17(1):e13688.
Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D, Rosebraugh M. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC rheumatology. 2018 Dec;2:1-1.
Imada K, Leonard WJ. The jak-STAT pathway. Molecular immunology. 2000 Jan 1;37(1-2):1-1.
Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, Horvath CM, Darnell JE, Stark GR, O’Shea JJ. The JAK-STAT pathway at 30: Much learned, much more to do. Cell. 2022 Oct 13;185(21):3857-76.
Huang IH, Chung WH, Wu PC, Chen CB. JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. Frontiers in immunology. 2022 Dec 8;13:1068260.
De Greef A, Ghislain PD, de Montjoye L, Baeck M. Real-life effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults. Advances in Therapy. 2023 May;40(5):2509-14.
Huang Y, Cai L, Wu X, Chen C. Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2023 Dec 1;40(6):725-33.
Huang L, Zhao D, Lin H, Zheng H, Li X, Chen L, Tang P. Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis in adolescents: A systematic review and meta-analysis of randomized controlled trials. Medicine. 2024 Sep 20;103(38):e39826.
Zhao DJ, Li X, Lin HX, Zheng H, Zhou D, Tang P. Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review. Plos one. 2024 Jul 26;19(7):e0306463.
Harb H, Chatila TA. Mechanisms of dupilumab. Clinical & Experimental Allergy. 2020 Jan;50(1):5-14.
Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. Journal of the American Academy of Dermatology. 2018 Mar 1;78(3):S28-36.
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. New England Journal of Medicine. 2014 Jul 10;371(2):130-9.
Gao Q, Zhao Y, Zhang J. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Heliyon. 2023 Jun 1;9(6).
Sedeh FB, Henning MA, Jemec GB, Ibler KS. Comparative efficacy and safety of monoclonal antibodies and janus kinase inhibitors in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. Acta Dermato-Venereologica. 2022 Aug 24;102:2075.
Tsai SY, Phipatanakul W, Hawryluk EB, Oyoshi MK, Schneider LC, Ma KS. Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study. Journal of Allergy and Clinical Immunology. 2024 Nov 1;154(5):1195-203.
Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatologic Therapy. 2022 Sep;35(9):e15636.
Grzelka M, Plizga J, Głuszczyk A, Makłowicz A, Kopczyńska E, Szpulak A, Frańczuk A, Głoskowska J, Kuleta K, Karkos P. The Upadacitinib-New Janus Kinase Inhibitor-Literature Review. Quality in Sport. 2024 Aug 28;21:54037-.
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2021 Jun 5;397(10290):2169-81.
Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, Patel A, Shen J, Girgis IG, Banerjee S, Throup J. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatology and Therapy. 2021 Oct;11(5):1763-76.
Kirchhof MG, Prajapati VH, Gooderham M, Hong CH, Lynde CW, Maari C, Turchin I, Papp KA. Practical recommendations on laboratory monitoring in patients with atopic dermatitis on oral JAK inhibitors. Dermatology and Therapy. 2024 Sep;14(9):2653-68.
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Gold LF. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA dermatology. 2022 Apr 1;158(4):404-13.
Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatology and Therapy. 2023 Mar;13(3):729-49.
Wang EQ, Le V, Winton JA, Tripathy S, Raje S, Wang L, Dowty ME, Malhotra BK. Effects of renal impairment on the pharmacokinetics of abrocitinib and its metabolites. The Journal of Clinical Pharmacology. 2022 Apr;62(4):505-19.
Wang EQ, Le V, O'Gorman M, Tripathy S, Dowty ME, Wang L, Malhotra BK. Effects of hepatic impairment on the pharmacokinetics of abrocitinib and its metabolites. The Journal of Clinical Pharmacology. 2021 Oct;61(10):1311-23.
Napolitano M, Ruggiero A, Fontanella G, Fabbrocini G, Patruno C. New emergent therapies for atopic dermatitis: a review of safety profile with respect to female fertility, pregnancy, and breastfeeding. Dermatologic Therapy. 2021 Jan;34(1):e14475.
Tan AJ, Streicher JL, Merola JF, Noe MH. Vaccine considerations for adult dermatology patients on immunosuppressive and immunomodulatory therapies: a clinical review. Dermatology online journal. 2021 Sep 9;27(9):10-5070.
Dillon KA. A comprehensive literature review of JAK inhibitors in treatment of alopecia areata. Clinical, Cosmetic and Investigational Dermatology. 2021 Jun 25:691-714.
Chiricozzi A, Faleri S, Saraceno R, Bianchi L, Buonomo O, Chimenti S, Chimenti MS. Tofacitinib for the treatment of moderate-to-severe psoriasis. Expert review of clinical immunology. 2015 Apr 3;11(4):443-55.
Hussain S. A NARRATIVE REVIEW ON EVALUATING THE SAFETY OF JANUS KINASE (JAK) INHIBITORS IN DERMATOLOGICAL PRACTICE: A CLINICAL AND LABORATORY PERSPECTIVE. Student's Journal of Health Research Africa. 2024 Mar 31;5(3):6-.
Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Frontiers in immunology. 2021 Nov 18;12:790125.
Motamed-Sanaye A, Khazaee YF, Shokrgozar M, Alishahi M, Ahramiyanpour N, Amani M. JAK inhibitors in lichen planus: a review of pathogenesis and treatments. Journal of Dermatological Treatment. 2022 Nov 17;33(8):3098-103.
Balestri R, Bortolotti R, Rech G, Girardelli CR, Zorzi MG, Magnano M. Treatment of oral erosive lichen planus with upadacitinib. JAMA dermatology. 2022 Apr 1;158(4):457-8.
Sohn A, Bouché N, Lewitt GM, Song EJ. Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure. JAAD Case Reports. 2024 Sep 1;51:97-9.
Zhou AE, Katsetos M, Lu J. Case of recalcitrant amyopathic dermatomyositis treated with upadacitinib. JAAD Case Reports. 2024 Dec 1;54:80-1.
Martora F, Scalvenzi M, Ruggiero A, Potestio L, Battista T, Megna M. Hidradenitis suppurativa and JAK inhibitors: a review of the published literature. Medicina. 2023 Apr 20;59(4):801.
Zhang T, Liu X, Zhang L, Jiang X. Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea. Frontiers in Immunology. 2024 Jul 9;15:1416004.
Mohamed ME, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clinical Pharmacokinetics. 2016 Dec;55:1547-58.
Mohamed ME, Jungerwirth S, Asatryan A, Jiang P, Othman AA. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. British Journal of Clinical Pharmacology. 2017 Oct;83(10):2242-8.
Mohamed ME, Klünder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clinical pharmacokinetics. 2020 May;59:531-44.
